Ashmanie Mahatoo
Neurology · Farmington, CTNPI 1699124156
Payments from drug & device makers
What this record shows
This record is dominated by grants: $88,500 of the $92,024 with a category attached, or 96.2%. Biogen accounts for 96.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $88,554 and has fallen 98.5% since, to $1,338 in 2025. Among neurology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $469.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$89K
- Novartis$796
- TG Therapeutics, Inc.$626
- Bristol Myers Squibb$546
- EMD Serono, Inc.$231
- Genentech, Inc.$165
- plus $506 from 7 others
Across 11 payments — averaging $3568.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- TG Therapeutics, Inc.$39K
What the payments were for
- Grants$88,50096%
- Food & beverage$3,5244%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 42 | $89,152 |
| Novartis | 54 | $796 |
| TG Therapeutics, Inc. | 24 | $626 |
| Bristol Myers Squibb | 43 | $546 |
| EMD Serono, Inc. | 11 | $231 |
| Genentech, Inc. | 6 | $165 |
| MML US, Inc. | 1 | $135 |
| AstraZeneca | 4 | $114 |
| Genentech USA, Inc. | 4 | $87 |
| Amgen(2 entities) | 3 | $70 |
| AbbVie | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Boston Scientific | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$92,024 in reported general payments places this provider in the 90th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 103 | $1,204,553 |
| Avonex (4 Pack)Interferon Beta-1a | 39 | $310,138 |
| TecfideraDimethyl Fumarate | 31 | $285,399 |
| VumerityDiroximel Fumarate | 25 | $228,885 |
| AubagioTeriflunomide | 18 | $200,385 |
| CopaxoneGlatiramer Acetate | 22 | $159,745 |
| Plegridy PenPeginterferon Beta-1a | 12 | $153,462 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 17 | $141,010 |
| AmpyraDalfampridine | 23 | $129,632 |
| Teriflunomide | 84 | $115,754 |
| Dimethyl Fumarate | 59 | $56,404 |
| Glatiramer Acetate | 20 | $53,515 |
| Dalfampridine ErDalfampridine | 152 | $50,554 |
| FingolimodFingolimod Hcl | 33 | $27,839 |
| GlatopaGlatiramer Acetate | 11 | $15,177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Tecfidera, Vumerity | $89,152 | $824,42395 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 280 neurology providers in Connecticut.
Other neurology in Farmington
- Wanda Castro-BorreroFarmington$553K
- Amanda Hernandez-JonesFarmington$303K
- Jaime Imitola HerreraFarmington$53K
- Hamza CobanFarmington$17K
- Matthew ImperioliFarmington$13K
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Derek SmithNorwich$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.